Emerging infectious disease research can raise unique issues during institutional review board (IRB) review. IRB members must review this type of protocol quickly and efficiently so that the research can begin as soon as possible. The risks and benefits must be clearly outlined in the informed consent form (ICF) to ensure participant comprehension. Special considerations during IRB review may include the inclusion and exclusion criteria, reimbursement and compensation for participants, and the possibility of utilizing technology to reduce the amount of travel expected of participants. While there are many moving parts to research involving emerging infectious diseases, keeping these considerations in mind will help appropriately inform potential participants of risks and benefits and move this vital research forward as quickly as possible.
To learn more about these issues, read the full article on Advarra’s website.